Cabazitaxel

Company: HangZhou HuiSheng Biotech Pharmaceutical Co., Ltd
Country: China (Mainland)
Business Type: Hangzhou Huisheng Biotech Pharmaceutical Co.,Ltd
Market: The Middle East,Europea,Russia,and South America and US market
Founded Year: 2002
Contact: Tibi Teng

Cabazitaxel

183133-96-2

C45H57NO14

Cabazitaxel is a semisynthetic taxane derivative that acts as a microtubule inhibitor. It binds to tubulin, promoting the assembly of tubulin into microtubules and inhibiting their disassembly, which results in microtubule stabilization, the inhibition of cell division, cell cycle arrest and the arrest of tumour proliferation. Cabazitaxel demonstrated antitumour activity against advanced human tumours xenografted in mice. As well as being active in docetaxel-sensitive tumours, cabazitaxel showed activity in tumour models insensitive to chemotherapy, including docetaxel. Cabazitaxel also penetrates the blood-brain barrier to a greater extent than docetaxel.